Issues in the mortality analysis of randomized controlled trials of cancer screening

https://doi.org/10.1016/0197-2456(94)90014-0Get rights and content

Abstract

This paper is concerned with the analysis and interpretation of randomized controlled trials (RCTs) of periodic screening programs for the early detection of cancer in which there is a lengthy follow-up period without screening being offered. That is, screening is offered for a limited time with a subsequent follow-up period during which the cancer mortality is observed. The paper focuses on tests for a mortality reduction due to screening. Two approaches are presented, one based on the experience of all those randomized to the test and control groups, and the other based on the experience of selected groups of cancer cases found during the trial. In the latter approach it is necessary that the two groups selected for analysis be comparable groups of cancers. The concept of comparability is discussed with emphasis on factors that determine comparability and on ways to assess it. Examples from completed cancer screening RCTs are used to illustrate the ideas and methods presented.

References (16)

  • PC Prorok et al.

    Concepts and problems in the evaluation of screening programs

    J Chron Dis

    (1981)
  • JL Aron et al.

    An analysis of the mortality effect in a breast cancer screening study

    Int J Epidemiol

    (1986)
  • S Shapiro

    Periodic Screening for Breast Cancer

  • S Shapiro et al.

    Periodic breast cancer screening

    Arch Environ Health

    (1967)
  • S Shapiro et al.

    Periodic breast cancer screening in reducing mortality from breast cancer

    JAMA

    (1971)
  • AS Morrison

    Screening in Chronic Disease

    (1985)
  • P Armitage

    Statistical Methods in Medical Research

    (1971)
  • DR Cox et al.

    The Statistical Analysis of Series of Events

    (1966)
There are more references available in the full text version of this article.

Cited by (27)

  • Computed Tomography Screening: The International Early Lung Cancer Action Program Experience

    2015, Thoracic Surgery Clinics
    Citation Excerpt :

    They do this by choosing a cutoff for the difference in the mortality rates that is considered to be clinically important (eg, 20% in the NLST). This difference influences the study design as to the number of participants, how many rounds of screening, and length of follow-up that need to be provided.52 All of these design parameters (significant mortality reduction, number of years of screening, and follow-up) must be determined in advance of the actual trial.

  • Assessment of lung-cancer mortality reduction from CT Screening

    2011, Lung Cancer
    Citation Excerpt :

    Once screening stops, lung-cancer deaths are expected to increase and will ultimately reach the same rate as in the absence of screening. Randomized controlled screening trials which typically provide a limited number of rounds of screening are not immune to these concerns [24–27]. This report is the first known report on lung cancer mortality based on a age-, sex-, and smoking history-adjusted approach comparing screening with two unscreened cohorts.

  • Epidemiologic Methods: The Essentials

    2022, Epidemiologic Methods: The Essentials
  • Screening Theory and Study Design: The Basics

    2021, Cancer Screening: Theory and Practice
View all citing articles on Scopus
View full text